Technical Analysis for OVIT - Oncovista Innovative Therapies I

Grade Last Price % Change Price Change
grade C 0.0272 -39.56% -0.0178
OVIT closed down 39.56 percent on Tuesday, September 10, 2019, on 1 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical OVIT trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 200 DMA Bullish -39.56%
Crossed Above 20 DMA Bullish -39.56%
Crossed Above 50 DMA Bullish -39.56%

Older signals for OVIT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
OncoVista Innovative Therapies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The Company's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The Company's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The Company's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.
Medicine Biotechnology Branches Of Biology Cancer Clinical Medicine Biopharmaceutical Tumor Biomarkers Chemical Pathology Cordycepin Polymerase
Is OVIT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.0625
52 Week Low 0.0065
Average Volume 48,859
200-Day Moving Average 0.0286
50-Day Moving Average 0.0291
20-Day Moving Average 0.0316
10-Day Moving Average 0.0341
Average True Range 0.0108
ADX 11.65
+DI 36.135
-DI 26.5387
Chandelier Exit (Long, 3 ATRs ) 0.0126
Chandelier Exit (Short, 3 ATRs ) 0.0506
Upper Bollinger Band 0.0464
Lower Bollinger Band 0.0168
Percent B (%b) 0.35
BandWidth 93.670886
MACD Line 0.0017
MACD Signal Line 0.0015
MACD Histogram 0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0272
Resistance 3 (R3) 0.0272 0.0272 0.0272
Resistance 2 (R2) 0.0272 0.0272 0.0272 0.0272
Resistance 1 (R1) 0.0272 0.0272 0.0272 0.0272 0.0272
Pivot Point 0.0272 0.0272 0.0272 0.0272 0.0272
Support 1 (S1) 0.0272 0.0272 0.0272 0.0272 0.0272
Support 2 (S2) 0.0272 0.0272 0.0272 0.0272
Support 3 (S3) 0.0272 0.0272 0.0272
Support 4 (S4) 0.0272